In this issue:
Efficacy and safety of upadacitinib in patients with AS
Treat-to-target in real-life PsA patients
The value of correctly diagnosing axSpA for patients and society
Prevalence and risk factors associated with PsA among patients with psoriasis
Influence of sex on early AS
Persistence of biologics in the treatment of PsA
Safety surveillance of tofacitinib over 9 years in patients with PsA
Patients’ needs concerning patient education in axSpA
Real-world evidence for secukinumab in UK patients with PsA
Student-led clinics to accelerate diagnosis and treatment of axSpA
Please login below to download this issue (PDF)